These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24038016)

  • 21. The effect of statins on high-risk atherosclerotic plaque associated with low endothelial shear stress.
    Takahashi S; Papafaklis MI; Sakamoto S; Antoniadis AP; Coskun AU; Feldman CL; Stone PH
    Curr Opin Lipidol; 2011 Oct; 22(5):358-64. PubMed ID: 21841484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colchicine in Stable Coronary Artery Disease.
    Fiolet ATL; Nidorf SM; Mosterd A; Cornel JH
    Clin Ther; 2019 Jan; 41(1):30-40. PubMed ID: 30396516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
    Duchatelle V; Kritikou EA; Tardif JC
    Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
    Bai W; Zheng X; Zhou L; Li H
    Can J Physiol Pharmacol; 2012 Feb; 90(2):131-9. PubMed ID: 22309388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic effects of statins: moving beyond cholesterol control.
    Garcia PJ
    Curr Atheroscler Rep; 2005 Feb; 7(1):34-9. PubMed ID: 15683600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation.
    Meyer-Lindemann U; Mauersberger C; Schmidt AC; Moggio A; Hinterdobler J; Li X; Khangholi D; Hettwer J; Gräßer C; Dutsch A; Schunkert H; Kessler T; Sager HB
    Front Immunol; 2022; 13():898690. PubMed ID: 35860249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week.
    Nelson K; Fuster V; Ridker PM
    J Am Coll Cardiol; 2023 Aug; 82(7):648-660. PubMed ID: 37558377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of aspirin, statins, colchicine, and IL-1 inhibitors in prevention of cardiovascular events: a systematic integrative review.
    Arboleda V; Hackworth A; Bonnice S; Gonzalez V; Cabrera D; Colletti C; Baxter C; Aleman Oliva C; Kabir S; Huang J; Khan A; Filoramo S; Ecoff S; Demory Beckler M; Kesselman MM
    J Osteopath Med; 2024 Mar; 124(3):97-106. PubMed ID: 37877246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Statins in the management of dyslipidemias].
    Scheen AJ
    Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins and stroke prevention.
    Paciaroni M; Hennerici M; Agnelli G; Bogousslavsky J
    Cerebrovasc Dis; 2007; 24(2-3):170-82. PubMed ID: 17596685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.